Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.36 |
| ▸ | GAK | O14976 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10015199 | 0.84 | ADORA1 (0.39) | PDGFRBNPC1PDGFRAMAPTRAB9A | |
| SCHEMBL288379 | 0.82 | MEN1 (0.50) | MAPTKMT2AL3MBTL1ADORA1ADORA2A | |
| SCHEMBL289476 | 0.80 | TDO2 (0.44) | PDGFRBPDGFRAMAPTKMT2AL3MBTL1 | |
| SCHEMBL288637 | 0.78 | F2 (0.40) | PDGFRBNPC1RAB9AKMT2AADORA1 | |
| SCHEMBL15433942 | 0.78 | CYP19A1 (0.39) | NPC1MAPTRAB9AKMT2AL3MBTL1 | |
| SCHEMBL288188 | 0.78 | RAC1 (0.49) | PDGFRBNPC1MAPTRAB9AKMT2A | |
| SCHEMBL289177 | 0.78 | SMN1; SMN2 (0.43) | NPC1MAPTRAB9AKMT2AL3MBTL1 | |
| SCHEMBL289558 | 0.77 | TDO2 (0.46) | NPC1RAB9AKMT2AL3MBTL1CYP19A1 | |
| SCHEMBL289422 | 0.77 | KDM4E (0.52) | NPC1MAPTRAB9AKMT2AADORA1 | |
| SCHEMBL298911 | 0.76 | PLAU (0.44) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427434-B1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | BOEHRINGER INGELHEIM INT (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-2427434-B1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | BOEHRINGER INGELHEIM INT (DE) | 2017-05-31 | — | — | EP | disclosed |
| US-8633320-B2 | Process for preparing bromo-substituted quinolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-8633320-B2 | Process for preparing bromo-substituted quinolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-20120165534-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165534-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| EP-2427434-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | Boehringer Ingelheim International GmbH (DE) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129451-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129451-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165534-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | HCCS, CYP3A7, ABL1 | PDGFRB 530/4885NPC1 298/4885PDGFRA 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.